Replies to post #36134 on Biotech Values

[gofishmarko]

re; ITMN abstract #1134

They reported some promising results last year in nonresponders , using ifn-gamma ( Actimmune ) plus Infergen. I guess they figure peg-ifn is just as good for their purposes since they dumped Infergen.

Actimmune has anti-fibrotic effects , presumably leading to better liver histology vs. controls , so they have two shots on goal by using it in HCV , the other being the possibility of improved SVR rates.

Ifn-gamma is a Th-1 cytokine and a Th-1 type immune response is associated with better outcomes in viral disease , so I guess that's what triggered the interest in it. It tends to downregulate TGF-beta , which can be immunosuppressive and contribute to tolerance.

Add Actimmune to the list of suspects for IDIX' 'creative approach' for nonresponders. I forgot that it was an approved drug.